---
schema_version: "secwatch.filing_event.v1"
accession: "0001087294-26-000011"
form_type: "8-K"
ticker: "CPIX"
cik: "0001087294"
company_name: "CUMBERLAND PHARMACEUTICALS INC"
filed_at: "2026-02-04T23:59:59+00:00"
generated_at: "2026-05-16T04:47:55.090008+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cumberland Pharma gets FDA Fast Track for ifetroban in DMD heart disease

## Summary
- FDA Fast Track Designation granted for ifetroban targeting fatal heart disease in Duchenne muscular dystrophy.
- Designation follows previous Orphan Drug and Rare Pediatric Disease Designations for same indication.
- Phase 2 FIGHT DMD trial showed 5.4% improvement in left ventricular ejection fraction over 12 months.
- Fast Track enables expedited review, rolling submission, and more frequent FDA interactions.

## SEC filing metadata
- accession: 0001087294-26-000011
- form_type: 8-K
- ticker: CPIX
- cik: 0001087294
- company_name: CUMBERLAND PHARMACEUTICALS INC
- filed_at: 2026-02-04T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1087294/000108729426000011/0001087294-26-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1087294/000108729426000011/cpix-20260204.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001087294-26-000011
- JSON: https://secwatch.observer/filing/0001087294-26-000011.json
- Plain text: https://secwatch.observer/filing/0001087294-26-000011.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.